White Paper: Compliance Strategy

A Framework for Reassessing Outsourcing Strategies to Manage Regulatory and Quality Needs in the "New Normal"

Before the pandemic, medical device, pharmaceutical and diagnostics firms were already laboring to meet regulatory deadlines. COVID-19 introduced new challenges that needed immediate attention. Demand for essential medical devices such as personal protective equipment and ventilators rose, while delayed elective procedures led to a lull for some medical device segments.

This white paper covers:

  • The short- and longer-term regulatory and quality
    impact of the COVID-19 pandemic on the life sciences market
  • Review of a series of areas where regulatory affairs and quality assurance professionals might consider reviewing their outsource resourcing balance

Medical device and IVD manufacturers of all types and sizes can benefit from the unique insights presented in this paper. Fill out the form to download your copy today.

Meet the Author:

Nancy_Morrison_1-min-429968-editedNancy Morrison, RAC
Vice President, Intelligence & Innovation

Nancy has more than 30 years of quality and regulatory experience in the medical industry with U.S. and global regulatory submission experience. She has spent the last nine years with RQM+, working with startup, mid-size and multinational medical device and combination product companies. Nancy has been providing EU MDR and IVDR leadership in developing solutions and implementing the regulations at small and large organizations.

Fill out the form to download the white paper